cancer cell

Recent News

May 2018

Francesca Cavallaro joins aTen Therapeutics from the University of Edinburgh to undertake a 3-month work-based MSc project investigating the target of our novel antibody.

May 2018

aTen Therapeutics attends the Scottish Life Sciences awards in Glasgow.

Tensinomab product logo

aTen Therapeutics’ lead candidate Tensinomab is a humanised single chain variable fragment (scFv) monoclonal antibody.

Tensinomab selectively modulates the angiotensin II Type 1 receptor (AT1R) which plays a central role in major diseases. In non-clinical testing, we have shown that Tensinomab has potential to treat a broad range of serious medical conditions.

Our lead development programme uses Tensinomab to treat primary cancers and protect against developing metastases, a major cause of cancer death.

In parallel, our development team is researching ATIR modulation to treat other major diseases.

There is mounting evidence demonstrating Tensinomab’s potential to become a significant new therapeutic agent and the aTen Therapeutics team is committed to exploring and exploiting this potential to extend and improve lives.

info@atentherapeutics.com

© aTen Therapeutics 2018. All rights reserved